Gilead Sciences (NASDAQ:GILD) Lifted to Hold at BidaskClub

BidaskClub upgraded shares of Gilead Sciences (NASDAQ:GILD) from a sell rating to a hold rating in a report published on Friday morning, BidAskClub reports.

A number of other analysts have also recently commented on the company. BMO Capital Markets set a $82.00 price objective on Gilead Sciences and gave the company a buy rating in a research report on Wednesday, July 31st. Mizuho set a $88.00 price objective on Gilead Sciences and gave the company a buy rating in a research report on Monday, July 15th. Goldman Sachs Group cut Gilead Sciences from a neutral rating to a sell rating and reduced their price objective for the company from $70.00 to $60.00 in a research report on Tuesday, May 28th. ValuEngine cut Gilead Sciences from a hold rating to a sell rating in a research report on Wednesday, September 4th. Finally, JPMorgan Chase & Co. reiterated a buy rating and set a $85.00 price objective on shares of Gilead Sciences in a research report on Wednesday, July 31st. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $82.24.

Gilead Sciences stock opened at $65.88 on Friday. The stock has a market cap of $84.04 billion, a PE ratio of 10.71, a price-to-earnings-growth ratio of 3.15 and a beta of 1.10. The company has a debt-to-equity ratio of 1.13, a quick ratio of 3.67 and a current ratio of 3.76. Gilead Sciences has a one year low of $60.32 and a one year high of $79.61. The stock has a fifty day moving average of $64.49 and a 200 day moving average of $65.45.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $1.68 by $0.14. The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.54 billion. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. Gilead Sciences’s revenue for the quarter was down 2.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.91 earnings per share. As a group, sell-side analysts predict that Gilead Sciences will post 6.66 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.83%. The ex-dividend date is Thursday, September 12th. Gilead Sciences’s dividend payout ratio is presently 40.98%.

In other Gilead Sciences news, Director Olsen Per Wold sold 4,908 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $63.91, for a total transaction of $313,670.28. Following the completion of the sale, the director now owns 102,762 shares of the company’s stock, valued at $6,567,519.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total value of $468,504.00. Following the sale, the executive vice president now directly owns 34,398 shares of the company’s stock, valued at approximately $2,238,277.86. The disclosure for this sale can be found here. Insiders have sold 12,716 shares of company stock valued at $821,299 in the last three months. 0.20% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the business. Advisors Preferred LLC bought a new position in shares of Gilead Sciences in the second quarter worth about $26,000. Weaver Consulting Group bought a new position in shares of Gilead Sciences in the first quarter worth about $34,000. Trustcore Financial Services LLC bought a new position in shares of Gilead Sciences in the first quarter worth about $34,000. Legacy Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter worth about $37,000. Finally, Evolution Wealth Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter worth about $46,000. 79.57% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: What is a Reverse Stock Split?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)